-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II

Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 2, 2018: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Fangli Chen, MD, PhD1*, Xue Wu, PhD1*, Rogozea Adriana1*, Bin Guo, PhD2, H. Scott Boswell, MD3, George A. Calin, MD, PhD4*, Mircea Ivan, MD, PhD5* and Heiko Konig, MD, PhD1

1Indiana University Simon Cancer Center, Indianapolis, IN
2Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN
3Indiana Cancer Research Inst., Indianapolis, IN
4M.D. Anderson Cancer Center, Houston, TX
5Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN

Cuiqing Fan, PhD1,2*, Xiongwei Cai, PhD2*, Feng Zhang, PhD candidate3*, Cindy Hochstetler, PhD candidate2, Xiaoyi Chen, PhD2*, Fukun Guo, PhD2, Weidong Tian, PhD2,3* and Yi Zheng, PhD2

1Institute of Pediatrics, Children's Hospital of Fudan University, Shanghai, China
2Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH
3Department of Biostatistics and Computational Biology, School of Life Science, Fudan University, Shanghai, China

Lais P Ghiraldeli, MS1*, Rebecca G. Anderson, B.S.2*, Kristin M. Pladna, M.S.2* and Timothy S. Pardee, MD, PhD3,4

1Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem
2Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC
3Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC
4Rafael Pharmaceuticals, Newark, NJ

Riikka Karjalainen1*, Minxia Liu1*, Ashwini Kumar, MRes1*, Alun Parsons1*, Liye He1*, Dishaben Rameshbhai Malani, MSc1*, Mika Kontro, MD2,3*, Kimmo Porkka, MD, PhD2,3 and Caroline A Heckman, PhD1

1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
2Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
3Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland

Weiguo Zhang, MD, PhD1, Guopan Yu, MD., PhD.2*, Hongying Zhang, MD3*, Charlie Ly, BS2*, Bin Yuan2*, Vivian Ruvolo, MS2*, Sujan Piya, PhD4, Seemana Bhattacharya, PhD2*, Qi Zhang, PhD2*, Gautam Borthakur, MD5, Venkata Lokesh Battula, PhD6, Marina Y. Konopleva, MD, PhD5, William G Rice, PhD3 and Michael Andreeff, MD, PhD2

1U.T.M.D. Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Aptose Biosciences, Inc., San Diego, CA
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Pearland, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Section of Molecular Hematology and Therapy, Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX

Sukhraj Pal Singh Dhami, MSc, BSc1*, Andrea Tirincsi, MSc, BSc1*, Denis V Baev, PhD1*, Janusz Krawczyk, MD2, John Quinn, MD, PhD3* and Eva Szegezdi, PhD1*

1Apoptosis Research Centre, National University of Ireland, Galway, Galway, Ireland
2Department of Haematology, Galway University Hospital, Galway, Ireland
3Department of Haematology, Beaumont Hospital, Dublin, Ireland

Samantha Weber, BS1,2*, Anilkumar Gopalakrisnapillai, PhD1*, E. Anders Kolb, MD1 and Sonali Barwe, PhD, MSc1,2*

1Alfred I. duPont Hospital for Children, Wilmington, DE
2University of Delaware, Newark, DE

Anjali Cremer, MD1*, Jana M Ellegast, MD2*, Yana Pikman, MD3, Gabriela Alexe, PhD2*, Linda Ross, PhD2*, Amy Goodale4*, Federica Piccioni, PhD4*, Elizabeth S Frank2*, Thomas Oellerich, MD5* and Kimberly Stegmaier, MD2,4,6

1Dana-Farber Cancer Institute, Brookline, MA
2Dana-Farber Cancer Institute, Boston, MA
3Dana Farber Cancer Institute, Boston, MA
4Broad Institute of MIT and Harvard, Cambridge, MA
5University Hospital Frankfurt, Department of Medicine II, Hematology-Oncology, Frankfurt am Main, Germany
6Boston Children's Hospital, Boston, MA

Giorgia Simonetti, PhD1*, Samantha Bruno2*, Carmine Onofrillo, PhD3*, Cristina Papayannidis4, Giovanni Marconi4, Michele Cavo, MD5*, Lorenzo Montanaro, MD, PhD3* and Giovanni Martinelli6

1Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
2Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”,, University of Bologna, Bologna, Italy
3Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
4Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
5Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “ L. and A. Seràgnoli”,, University of Bologna, Bologna, Italy
6Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Meldola, Italy

Yoko Tabe, MD, PhD1, Kotoko Yamatani, MD2*, Haeun Yang2*, Kaori Saito2*, Yuko Murakami-Tonami, MD3*, Koya Suzuki, PhD2,4*, Weiguo Zhang, MD, PhD5, Sonoko Kinjo, PhD6*, Kazuho Ikeo, PhD6*, Masaki Hosoya, PhD7*, Kaoru Mogushi, PhD8*, Shigeo Yamaguchi9*, Hironori Harada, MD, PhD10, Takashi Miida, MD, PhD2*, Neil Shah, MD11, Marina Y. Konopleva, MD, PhD12, Yoshihide Hayashizaki, MD, PhD13* and Michael Andreeff, MD, PhD14

1Department of Next Generation Hematology Laboratory Medicine, Graduate School of Medcine, Juntendo University, Tokyo, Japan
2Department of Clinical Laboratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
3Juntendo Univ., Tokyo, Japan
4Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Japan
5U.T.M.D. Anderson Cancer Center, Houston, TX
6Centers for Information Biology, National Institute of Genetics, Shizuoka, Japan
7Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan
8Department of Diagnostics and Therapeutics of Intractable Diseases, Graduate School of Medicine, Juntendo University, Tokyo, Japan
9Juntendo University of Medicine, Tokyo, Japan
10Department of Hematology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
11Georgetown University Hospital, Washington, DC
12Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
13Preventive Medicine & Diagnosis Innovation Program, RIKEN Center for Life Science Technoligies, Kanagawa, Japan
14Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Ami B. Patel, MD1, Anthony D. Pomicter, MS2*, Dongqing Yan3*, Anna M. Eiring, PhD3, Anca Franzini, PhD3*, Thomas O'Hare, PhD1 and Michael W. Deininger, MD, PhD1

1Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT
2Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT

Peter P. Ruvolo, PhD1, Huaxian Ma, MS2*, Vivian Ruvolo, MS3*, Xiaorui Zhang, BS2*, Hong Mu, MD, PhD2*, Tomoko Yasuhiro4*, Kohei Tanaka5*, Toshio Yoshizawa, PhD6, Weiguo Zhang, MD, PhD7, Jorge E. Cortes, MD2, Michael Andreeff, MD, PhD3 and Sean M Post, PhD2

1Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4ONO PHARMACEUTICAL CO., LTD., OSAKA, JPN
5Oncology Research Laboratories, Ono Pharmaceutical, Osaka, Japan
6Ono Pharmaceutical Co. Ltd., Osaka, JPN
7U.T.M.D. Anderson Cancer Center, Houston, TX

Kartika Venugopal, MS*, Jianping Li, MD, Daniil E Shabashvili, PhD*, Luisa M Posada*, Yang Feng, MS*, Daphne Dupere-Richer, PhD, Aditya Bele, PhD*, Jonathan D. Licht, MD and Olga A Guryanova, MD, PhD

UF Health Cancer Center, University of Florida College of Medicine, Gainesville, FL

Dan Cojocari, PhD, BSc1*, Sha Jin, MS2*, Julie J Purkal, MA3*, Relja Popovic, PhD4, Nari N Talaty, PhD5*, Yu Xiao, MS2*, Larry R Solomon, PhD3,6*, Erwin Boghaert, MS, MD3*, Joel D. Leverson, PhD7* and Darren C. Phillips, PhD2*

1Discovery Oncology, AbbVie Inc, North Chicago, IL
2Discovery Oncology, AbbVie Inc., North Chicago, IL
3Oncology Discovery, AbbVie Inc., North Chicago, IL
4Genomics Research Center, AbbVie Inc, North Chicago, IL
5Discovery Chemistry and Technologies, AbbVie Inc., North Chicago, IL
6Former AbbVie Employee, North Chicago, IL
7Oncology Development, AbbVie Inc., North Chicago, IL

Karlotta E Kahmann1*, Stefanie Kesper1*, Marco Luciani1*, Michael Möllmann1*, Hugh Y. Rienhoff Jr., MD2, Ulrich Dührsen, Prof, MD, PhD1* and Joachim R Göthert, MD1

1Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
2Imago Biosciences, San Francisco

Dijiong Wu1*, Keding Shao, M.D.2*, Qihao Zhou, M.D.3*, Jie Sun4*, Ziqi Wang2*, Fei Yan2*, Tingting Liu2*, Xiangping Wu5*, Baodong Ye6*, He Huang, MD, PhD4 and Yuhong Zhou7*

1Department of Hematology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
2First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
3Department of Hematology, Zhejiang Provincial People’s Hospital, Hangzhou, China
4Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5Department of Pathology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
6Department of Hematology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, CHN
7Department of Hematology, Zhejiang Provincial Hospital of TCM, Hangzhou, China

Claire Fritz1,2*, Scott M. Portwood, MS, MBA3*, Julie Adams, BS3*, Tara Cronin, BA3*, Linda Lutgen-Dunckley3*, Brandon L Martens, BS3*, Callum M. Sloss, PhD4, Krystal Watkins4*, Yelena Kovtun, PhD4, Sharlene Adams, PhD4* and Eunice S. Wang, MD5

1Department of Medicine, Case Western Reserve University, Buffalo, NY
2Case Western Reserve University, Cleveland, OH
3Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
4ImmunoGen, Inc., Waltham, MA
5Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

*signifies non-member of ASH